Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for lung cancer patients with brain tumors: drug combo enters final testing

NCT ID NCT06970639

Recruiting now Disease control Sponsor: Allist Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new drug called furmonertinib, given with chemotherapy, works better than the current standard drug osimertinib for people with a specific type of lung cancer (EGFR-mutant non-squamous NSCLC) that has spread to the brain. About 380 adults whose cancer has brain metastases will be randomly assigned to one of three treatment groups. The goal is to see which approach keeps the cancer from growing longer and is safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC PATIENTS WITH BRAIN METASTASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NSCLC PATIENTS WITH BRAIN METASTASIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guangdong Provincial People's Hospital

    RECRUITING

    Guangdong, Guangzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••